Aileron Therapeutics

Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company engaged in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

WATERTOWN, Mass., Oct. 24, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced new positive clinical data from its ongoing Phase 1b trial demonstrating clinical proof of concept that treatment with ALRN-6924 prior to second-line topotecan administration resulted in a protective effect against severe anemia, thrombocytopenia and neutropenia in patients with p53-mutated small cell lung cancer (SCLC). The results are being featured today in a late-breaking poster presentation entitled, “Prevention of Chemotherapy-induced Myelosuppression in SCLC Patients Treated with Dual MDM2/MDMX Inhibitor ALRN-6924” (online here) at the 32nd EORTC-NCI-AACR Annual (ENA 2020) Symposium on Molecular Targets and Cancer Therapeutics.

Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium

WATERTOWN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b proof-of-concept study of ALRN-6924 on Monday, October 26, 2020 at 8:30 a.m. ET. As previously announced by Aileron, the Phase 1b clinical data will be presented in a late-breaking poster presentation during the upcoming 32nd EORTC-NCI-AACR Annual (ENA 2020) Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 – 25, 2020. The abstract entitled, “Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDM2/MDMX inhibitor ALRN-6924,” (LBA96) will be presented starting Saturday, October 24 at 10:00 a.m. CEST (4:00 a.m. ET), on the ENA 2020 website.

Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium

Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher

WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featured in a late-breaking poster presentation during the 32nd EORTC-NCI-AACR Annual (ENA 2020) Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 – 25, 2020.

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

WATERTOWN, Mass., Sept.  21, 2020  (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor and current shareholder.

Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

Celldex Therapeutics

Emergent BioSolutions

Horizon Pharma

Novavax

Here we discuss five biotech companies recording impressive growth so far in 2020.

5 Biotech Stocks Up More Than 100% This Year So Far

WATERTOWN, Mass., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the second quarter ended June 30, 2020.

Aileron Therapeutics Reports Second Quarter 2020 Financial Results  and Provides Business Update

WATERTOWN, Mass., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month.

Aileron Therapeutics to Present at Two Upcoming Investor Conferences  in August

WATERTOWN, Mass., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today that it has completed enrollment in the dose optimization expansion cohort of its ongoing open-label Phase 1b clinical study of ALRN-6924. Aileron is focused on transforming the experience of chemotherapy for cancer patients by developing and delivering a novel chemoprotective medicine to protect against multiple chemotherapy-induced side effects. The proof-of-concept Phase 1b study is evaluating ALRN-6924 as a therapeutic agent administered ahead of chemotherapy to prevent chemotherapy-induced bone marrow toxicities, such as severe anemia, thrombocytopenia and neutropenia, in patients with p53-mutated small cell lung cancer (SCLC) who are being treated with topotecan. The protocol for this study consists of a phase 1b and a randomized, controlled phase 2; the Phase 1b has two parts: dose optimization and schedule optimization.

Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924

 -- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy’s off-target effects --     – In p53-mutant cancers, ALRN-6924 is designed to shield healthy cells from chemotherapy while preserving cancer cells’ susceptibility to chemotherapy –

Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan

WATERTOWN, Mass., June  10, 2020  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by the underwriter of their option to purchase an additional 1,071,149 shares at the public offering price of $1.10 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Aileron to 10,162,059 shares and increased the amount of gross proceeds to $11.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Aileron.

Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares

WATERTOWN, Mass., June  04, 2020  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $1.10 per share, for aggregate gross proceeds of $10.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Aileron. In addition, Aileron has granted the underwriter a 30-day option to purchase up to 1,363,636 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being sold by Aileron. The offering is expected to close on June 8, 2020, subject to the satisfaction of customary closing conditions.

Aileron Therapeutics Announces Pricing of Public Offering of Common Stock

WATERTOWN, Mass., June  03, 2020  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering. All of the shares are being offered by Aileron.

Aileron Therapeutics Announces Proposed Public Offering of Common Stock

CymaBay Therapeutics

Energy Focus

Mersana Therapeutics

MicroVision

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

5 Top Stocks Up 100%+ in May With More Room to Run

WATERTOWN, Mass., May  27, 2020  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients with small cell lung cancer (SCLC) against chemotherapy-induced toxicity, a concept known as chemoprotection (or myelopreservation).  The first patient has been enrolled into the expansion cohort, which was triggered by results from the ongoing trial that met protocol-specified criteria for expansion.  The Company expects to enroll approximately 8 patients into this dose optimization expansion cohort to further evaluate the selected dose for chemoprotection from topotecan-induced bone marrow toxicities.

Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent

Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial  of ALRN-6924 as a chemoprotection agent in cancer patients   - - -  Scheduled to report interim results from the dose optimization part of the Phase 1b/2 trial 2nd Quarter 2020, and planning final data readout in the fourth quarter of 2020  - - -  Company implemented measures to reduce operating expenses  to extend its cash runway to first quarter 2021   - - -

Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study   - - -   Final data readout from Phase 1b for both dose optimization and schedule optimization in Q4 2020  - - -  Updated corporate presentation available on the Company’s website

Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020

WATERTOWN, Mass., Dec.  18, 2019  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer, effective immediately. Mr. Wanstall has served as the Company’s Vice President of Finance and Operations and principal accounting officer since 2018.

Aileron Therapeutics Announces the Promotion of Richard J. Wanstall  to Chief Financial Officer and Treasurer

Aileron Therapeutics, Inc. (ALRN) CEO Manuel Aivado on Q3 2019 Results - Earnings Call Transcript

Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy

Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference

Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy.

Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th

Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer.

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

Final data expected in the second quarter of 2020 Final data expected in the second quarter of 2020

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

WATERTOWN, Mass., Sept.  24, 2019  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, today announced that an abstract on interim Phase 2a data for the Company’s lead product candidate, ALRN-6924, in combination with Pfizer’s IBRANCE® (palbociclib) in patients with MDM2-amplified cancers has been accepted for a poster presentation at the 2019 Congress of the European Society for Medical Oncology (ESMO), which is scheduled to be held in Barcelona, Spain, from September 27 – October 1, 2019.

Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology

WATERTOWN, Mass., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Manuel Aivado, MD, PhD, President & Chief Executive Officer, will  present a corporate overview and host one-on-one investor meetings at the H.C. Wainwright 21st Annual Global Investment Conference, being held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York, NY.  Details on the presentation are as follows:

News for Aileron Therapeutics Stock (ALRN)